Goldman Sachs trims Evotec voting rights to 13.7% from 13.71%
Evotec (XTRA:EVT) Stock Faces Deeper EBITDA Losses After Guidance Cut
EVT: Revenue and profitability declined sharply, with losses deepening and guidance lowered for 2026
Evotec H1 FY26 adjusted EBITDA loss widens to EUR 42.7 million; revenue drops 19.2% to EUR 300.1 million
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands
Evotec and Odyssey collaborate on AI-enabled R&D